Stanford plans collaboration with FDA
On Jan. 12, the Stanford biodesign program and the Stanford School of Medicine signed a memorandum of understanding (MOU) with the Food and Drug Administration (FDA). This memorandum gives both organizations a foundation that allows future collaboration on projects, such as working to improve the regulatory process for innovations in medical technology.
